Sotorasib and adagrasib target a specific cancer-causing mutation found in those with non-small-cell lung cancer and colorectal cancer.

Genomic testing can help customize treatment to target tumors.

Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.

The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.

The study helps explain how cancer cells adapt and tolerate treatment and identify combination therapies to improve outcomes in people.

To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.

MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.

First KRAS targeted therapy shows promise for lung and colon cancer

Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.